A Randomized Trial Assessing the Effectiveness of Ezetimibe in South Asian Canadians with Coronary Artery Disease or Diabetes: The INFINITY Study

Table 3

Absolute and percent change in lipid parameters from baseline to 6 weeks and from baseline to 12 weeks, by treatment group.

Parameter		EZE + Statin	STAT^2	𝑃 Value; (Between-Group)
		𝑛=28	𝑛=28
Six weeks, mmol/L (mean ± SD)
Total cholesterol	Absolute change	−0.59±0.82*	−0.50±0.54*	0.600
	% change	−13.84±17.81*	−10.93±11.38*	0.469
LDL-C	Absolute change	−0.50±0.74*	−0.39±0.46*	0.494
	% change	−18.82±26.99*	−13.55±16.08*	0.378
HDL-C	Absolute change	−0.04±0.12	−0.06±0.15	0.602
	% change	−4.02±10.63	0.42±40.28	0.575
Triglycerides	Absolute change	−0.31±0.75	−0.03±0.66	0.152
	% change	−9.96±29.24	0.73±39.26	0.253
Total Chol/HDL-C	Absolute change	−0.44±0.70*	−0.64±2.66	0.708
	% change	−10.07±15.80*	−5.34±20.77	0.341
		𝑛=29	𝑛=23
Twelve weeks, mmol/L (mean ± SD)**
Total cholesterol	Absolute change	−0.80±0.37*	−0.83±0.76*	0.917
	% change	−18.06±17.90*	−16.60±12.62*	0.741
LDL-C	Absolute change	−0.73±0.69*	−0.69±0.66*	0.830
	% change	−26.62±23.65*	−22.71±18.19*	0.517
HDL-C	Absolute change	0.018±0.29	−0.06±0.19	0.257
	% change	0.48±17.55	0.09±38.47	0.960
Triglycerides	Absolute change	−0.38±0.72*	−0.11±0.54	0.141
	% change	−14.58±28.78*	1.04±35.20	0.084
Total Chol/HDL-C	Absolute change	−0.80±0.81*	−0.95±2.42	0.757
	% change	−18.05±14.33*	−12.19±19.69*	0.220
		𝑛=27	𝑛=23
Twelve weeks sensitivity analysis,; mmol/L (mean ± SD)***
Total cholesterol	Absolute change	−0.77±0.86*	−0.82±0.76*	0.810
	% change	−17.38±18.36*	−16.60±12.62*	0.874
LDL-C	Absolute change	−0.72±0.70*	−0.69±0.66*	0.197
	% change	−26.34±24.31*	−22.71±18.19*	0.170
HDL-C	Absolute change	0.03±0.29	−0.06±0.19	0.761
	% change	1.28±17.31	0.88±38.47	0.864
Triglycerides	Absolute change	−0.37±0.74*	−0.11±0.54	0.559
	% change	−13.24±29.41	1.04±35.20	0.961
Total Chol/HDL-C	Absolute change	−0.80±0.79*	−0.95±2.42	0.125
	% change	−18.27±13.77*	−12.19±19.69*	0.207

LDL-C low density lipoprotein cholesterol, HDL-C high density lipoprotein cholesterol
* 𝑃 value based on One-Sample t-test (significantly different than zero). Alpha level of 0.025 to account for multiple comparisons
**12 weeks results account for 2 crossovers in treatment assignment, reflecting treatment actually received (Figure 2)
***12 weeks sensitivity analysis excluded the 2 crossovers and was conducted only on patients maintained in their respective treatment group.